Association of Endocrine Therapy and Dementia in Women with Breast Cancer.

PURPOSE: Prior studies have reported differing results regarding the association between endocrine therapy (ET) in the treatment of breast cancer and dementia risk. However, existing findings may be limited by common sources of bias and confounding. Here we investigate the association of ET utilized in the definitive setting to treat non-metastatic breast cancer with dementia risk accounting for multiple potential sources of bias and confounding. PATIENTS AND METHODS: We conducted a retrospective study in SEER-Medicare of women aged ≥ 66 years with non-metastatic breast cancer. We examined the risk of all-cause dementia among ET users versus non-ET users using multivariable regression models, accounting for the competing risk of death, and using a start of the follow-up period as 12-months following breast cancer diagnosis for both groups to avoid immortal time bias.
RESULTS: Among 25,777 individuals there were 2,869 incident dementia cases. We found a statistically significantly decreased risk of any dementia among ET users in unadjusted and adjusted models that completely attenuated when accounting for the competing risk of death (hazard ratio, 0.98; 95% confidence interval, 0.90-1.07).
CONCLUSION: When accounting for common sources of bias and confounding we did not find evidence to support an association between ET in the definitive treatment of non-metastatic breast cancer and dementia risk. These results suggest that ET may not be associated with dementia risk.

Introduction

Globally, breast cancer is the most common type of cancer diagnosed in women with over 270,000 new cases estimated in 2020 in the United States alone.1 However, despite this high incidence, the mortality rate for breast cancer remains low. Therefore, side effects from common treatments for breast cancer can have significant long-term public health implications.

Endocrine therapy (ET), which works to decrease the interaction of circulating hormones estrogen and progesterone with hormone-receptor positive breast cancer cells, is a mainstay of treatment for breast cancer that has been shown to reduce breast cancer mortality rates.2 Broadly, endocrine therapy typically includes selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). SERMS work by blocking the effect of estrogens in tissues and AIs work by preventing the enzymatic conversion of other hormones in the body into estrogen. Multiple epidemiological studies have shown an association between estrogens and cognitive health, including altered dementia risk associated with ET use to treat breast cancer. A nationwide population-based study in Taiwan among patients diagnosed with breast cancer found that tamoxifen users had a 17% relative reduction in dementia risk.3 Conversely, a Danish nationwide medical registries study among patients with breast cancer found no clear association between tamoxifen use and dementia risk.4 A recent study using Humana claims data examined 326,485 women with breast cancer and found a 12% relative dementia risk reduction.5 However, this and prior studies are limited by potential sources of bias through the inclusion of heterogenous populations (composition bias) such as those with local and metastatic disease, incompletely accounting for immortal time (immortal time bias), and the competing risk of death (competing risk bias).6–8 Here we utilize data from SEER-Medicare to investigate the association of ET utilized in the definitive setting to treat non-metastatic breast cancer with dementia risk accounting for multiple potential sources of bias and confounding.

Methods

We conducted a retrospective study in the Surveillance, Epidemiology and End Results (SEER)-Medicare linked dataset of women aged 66 year of age or older with non-metastatic breast cancer diagnosed from 2008–2015 (Figure 1). SEER-Medicare is a linkage dataset of cancer registries data containing clinical, demographic and cause of death information with Medicare claims data for covered health care services.

Figure 1

Flowchart with exclusion criteria to identify analytic cohort.

We compared ET users (received ET in the 12 months following breast cancer diagnosis per Part D claims data) to non-ET users. We defined ET as 1) AI only (anastrozole, exemestane, letrozole), 2) SERM only (tamoxifen, toremifene), and 3) AI and SERM. The primary outcome was incident all-cause dementia. Secondary analyses examined ET type (selective estrogen receptor modulators [SERMs], aromatase inhibitors) and dementia type (vascular dementia, Alzheimer’s dementia, other or unclassified dementia). The start of the follow-up period was 12-months following breast cancer diagnosis for both groups to avoid immortal time bias.6 Baseline patient characteristics were compared using a t-test or χ2 test. Hazard ratios (HRs) were calculated using multivariable adjusted Cox proportional hazards regression models with death from any cause as a competing event using the method of Fine and Gray.9 Models were adjusted for age, race, region, marital status, T stage, N stage, Charlson Comorbidity Index, treatment with radiation, surgery, or chemotherapy. We conducted sensitivity analyses using one-to-one nearest-neighbor propensity score matching. This study was institutional review board approved by MD Anderson Cancer Center and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. Tests were considered to be significant with a 2-sided P <.05. We used SAS version 9.4 and R version 4.0.0 to perform the analyses.

Results

The analytic cohort (Figure 1) included 25,777 individuals with median follow-up of 32 months (interquartile range, 32–78 months). Compared to the no-ET group (n=6,649), the ET group (n=19,128) was younger (74 versus 76 years), more likely to be white (88% versus 87%), married (47% versus 40%), have T1 disease (68% versus 66%), be node positive (24% versus 18%), undergo radiation therapy (65% versus 53%), and not undergo chemotherapy (22% versus 34%), p<0.001 for all (Table 1). There were 2,869 incident dementia cases including vascular dementia (n=159), Alzheimer’s (n=475) and other or unclassified dementia (n=2,235). 10.2% of individuals in the ET group and 13.9% of individuals in the no-ET were classified as having dementia in our study. We found a statistically significantly decreased risk of any dementia among ET users in unadjusted models (Table 2) that attenuated when accounting for confounders and the competing risk of death (HR, 0.98; 95% confidence interval [CI], 0.90–1.07). Results were consistent when examining vascular dementia (HR, 0.93; 95% CI, 0.74–1.16), Alzheimer’s (HR, 0.99; 95% CI 0.87–1.15), and other or unclassified dementia (HR 0.98; 95% CI 0.90–1.08). Association of ET subtype according to ET class are presented in . Sensitivity analysis using propensity score matching to examine ET use with any dementia showed similar results (HR 0.95; 95% CI 0.86–1.03). When stratifying our analysis by type of ET we observed an increased risk of dementia with SERMs (Table 2) that was no longer statistically significant with propensity score matching (HR, 1.16; 95% CI 0.99–1.35; p=0.056).

Table 1

Demographics

Characteristics	No Endocrine Therapy (n=6,649)	Endocrine Therapy (n=19,128)	p-value
Age at Diagnosis, years			<0.001
Mean (SD)	76.0 (7.4)	73.9 (6.2)
Median	75	73
66–69	1,557 (23.4)	5,746 (30)
70–74	1,683 (25.3)	5,842 (30.5)
75–79	1,300 (19.6)	3,921 (20.5)
80+	2,109 (31.7)	3,619 (18.9)
Race/Ethnicity			<0.001
White	5,763 (86.7)	16,819 (87.9)
Black	526 (7.9)	1,157 (6.1)
Other	360 (5.4)	1,152 (6)
Year of Diagnosis			<0.001
2008	798 (12)	1,809 (9.5)
2009	799 (12)	1,849 (9.7)
2010	772 (11.6)	2,016 (10.5)
2011	783 (11.8)	2,175 (11.4)
2012	804 (12.1)	2,200 (11.5)
2013	786 (11.8)	2,623 (13.7)
2014	919 (13.8)	3,082 (16.1)
2015	988 (14.9)	3,374 (17.6)
Region			<0.001
Midwest	980 (14.7)	2,470 (12.9)
Northeast	1,088 (16.4)	3,865 (20.2)
South	1,508 (22.7)	4,710 (24.6)
West	3,073 (46.2)	8,083 (42.3)
Marital Status			<0.001
Married	2,731 (41.1)	9,076 (47.5)
Not married	3,596 (54.1)	9,154 (47.9)
Unknown	322 (4.8)	898 (4.7)
Poverty (% with poverty)			0.211
Q1 (lowest poverty)	1,630 (24.5)	4,930 (25.8)
Q2	1,702 (25.6)	4,777 (25)
Q3	1,696 (25.5)	4,767 (24.9)
Q4	1,621 (24.4)	4,654 (24.3)
Education (% non-high school graduated)			0.349
Q1 (highest education)	1,709 (25.7)	4,841 (25.3)
Q2	1,735 (26.1)	4,830 (25.3)
Q3	1,641 (24.7)	4,816 (25.2)
Q4	1,564 (23.5)	4,641 (24.3)
T stage			<0.001
T0/Unknown	24 (0.4)	24 (0.1)
T1	4,415 (66.4)	13,045 (68.2)
T2	1,774 (26.7)	4,929 (25.8)
T3	250 (3.8)	727 (3.8)
T4	186 (2.8)	403 (2.1)
N stage			<0.001
N0	5,440 (81.8)	14,552 (76.1)
N1	873 (13.1)	3,477 (18.2)
N2	205 (3.1)	724 (3.8)
N3	125 (1.9)	353 (1.9)
Unknown	6 (0.1)	22 (0.1)
AJCC stage			0.102
I	4,119 (62)	11,581 (60.5)
II	2,005 (30.2)	5,931 (31)
III	525 (7.9)	1,616 (8.5)
ER status			<0.001
Positive	3,295 (49.6)	18,554 (97)
Negative	3,139 (47.2)	245 (1.3)
Unknown	215 (3.2)	329 (1.7)
Subtype			<0.001
HR+/HER2−	2,234 (33.6)	13,333 (69.7)
HR+/HER2+	200 (3)	1,243 (6.5)
HR−/HER2+	553 (8.3)	38 (0.2)
HR−/HER2−	1,688 (25.4)	72 (0.4)
Unknown	1,974 (29.7)	4,442 (23.2)
Charlson Comorbidity Scores			0.720
0	4,023 (60.5)	11,623 (60.8)
1	1,575 (23.7)	4,561 (23.8)
2+	1,051 (15.8)	2,944 (15.4)
Type of Endocrine Therapy (ET)			<0.001
None/Never	6,649 (100)	0 (0)
Selective Estrogen Receptor Modulators (SERM) only	0 (0)	1,762 (9.2)
Aromatase inhibitors only	0 (0)	15,058 (78.7)
SERM + AI	0 (0)	2,308 (12.1)
Chemotherapy use	2,287 (34.4)	4,250 (22.2)	<0.001
Radiation Therapy use	3,576 (53.8)	12,574 (65.7)	<0.001
Surgery			<0.001
None	224 (3.4)	529 (2.8)
Breast conservation	4,030 (60.6)	12,386 (64.8)
Mastectomy	2,395 (36)	6,213 (32.5)
Cardiovascular disease	1,931 (29)	5,052 (26.4)	<0.001
Diabetes	1,800 (27.1)	5,647 (29.5)	<0.001

Note: Data presented as No. (%) unless otherwise noted.

Abbreviation: SD, standard deviation.

Table 2

Association of Endocrine Therapy in the Treatment of Breast Cancer and Dementia Risk (n=25,777)

Model	HR	95% CI	P-value
Univariable	0.77	0.71–0.84	<0.001
Adjusted*	0.91	0.83–0.98	0.018
Adjusted with competing risk^	0.98	0.90–1.07	0.631
AI only (n=15,058)	0.94	0.86–1.03	1.00
SERM only (n=1,762)	1.18	1.03–1.36	0.02
SERM + AI (n=2,308)	1.00	0.87–1.15	0.98

Notes: *Adjusted for age, race, region, marital status, T stage, Index, treatment with radiation, surgery, or chemotherapy. ^Competing risk of death.

Abbreviations: AI, aromatase inhibitor; CI, confidence interval; HR, hazards ratio; SERM, selective estrogen receptor modulator.

Discussion

We did not find evidence to support an association between ET in the definitive treatment of non-metastatic breast cancer and dementia risk, which differs from some prior studies showing a protective effect.3,5 We found that 10.2% of individuals in the ET group and 13.9% of individuals in the no-ET had dementia, which is in line with the 11.5% of Medicare Fee‐for‐Service beneficiaries aged ≥65 years with dementia.10 Our analysis showed a protective effect of ET on dementia in fully adjusted models that completely attenuated when accounting for the competing risk of death, which is critical when examining incident outcomes in older individuals7 and was not accounted for in all prior studies. Furthermore, our use of a relatively homogenous cohort may be less susceptible to selection bias,8 and we designed our analysis to limit the impact of immortal time bias.6

Our study accounted for the competing risk of death when analyzing the association of ET use and dementia risk and this may primarily explain the difference between our results and those observed in prior studies showing a protective effect.5 A competing risk is an alternative outcome, such as death, that alters the probability of the outcome of interest. In traditional survival analyses individuals who are censored for any reason are considered at risk for the primary outcome for the remaining duration of the study. However, while individuals who are censored for being lost to follow-up may remain at risk for dementia, individuals who become deceased are no longer at risk for dementia. Modeling the risk of the outcome similarly for individuals lost to follow-up and who are deceased may not be appropriate, particularly when examining older populations at greater risk of death from any cause. Competing risk analysis accounts for the probability of the outcome, here dementia, in the presence of a competing risk, here death, and avoids overestimation of association effects.7 Our ability to replicate a protective effect of ET on dementia risk, which then completely attenuates when implementing a competing risk model, suggests that prior studies may have overestimated the association of ET and dementia risk by not accounting for the competing risk of death.

Prior studies have shown conflicting results regarding the association of ET in the treatment of breast cancer with altered dementia risk. A population-based study in Taiwan examined 24,197 patients diagnosed with breast cancer and found that tamoxifen users had a 17% relative reduction in dementia risk.3 Interestingly, they found that a longer duration tamoxifen resulted in further increased risk and they found no association between dementia risk and treatment with AIs. Whether SERMs act on the brain to impact brain function, an effect which could vary based on menopausal status, remains an area of active investigation.11,12 SERMs are known to have tissue specific estrogenic and anti-estrogenic effects and therefore the potential to both positively and adversely impact cognitive function. Conversely, a Danish nationwide medical registries study examined 16,419 patients with breast cancer and found a weak association between tamoxifen therapy and dementia risk (HR, 1.4; 95% CI, 1.0–1.9) that completely attenuated when accounting for death as a competing risk (SHR, 1.0; 95% CI 0.76–1.4).4 A recent study using Humana claims data examined 326,485 women with breast cancer and found a 12% relative dementia risk reduction in adjusted models. However, this study was unable to account for the competing risk of death.5

Our study has limitations. Our findings may not be generalizable to younger populations as we only examined individuals ≥ 66 years of age. Additionally, our ability to examine the association of SERM and dementia risk was limited by low power and should be further investigated in future studies. Our study design was retrospective in nature and therefore may still be subject to bias and residual confounding. We were unable to account for smoking in our adjusted models, which is a potential confounding factor. Additionally, our study had a relatively short duration of follow-up and it is possible that we were therefore unable to detect longer term impacts of ET on dementia risk.

In conclusion, when accounting for common sources of bias and confounding, in particular competing risks, we did not find evidence to support an association between ET in the definitive treatment of non-metastatic breast cancer and dementia risk. Future studies powered to explore SERM use and dementia risk, particularly among younger individuals, are needed.